Abdominal adiposity and the polycystic ovary syndrome

Trends in Endocrinology and Metabolism

Volumn 18, Issue 7, 2007, Pages 266-272

  Escobar Morreale, Héctor F ^a   Millán, José L San ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FLUTAMIDE; GONADORELIN AGONIST; INSULIN; INSULIN SENSITIZING AGENT; LEPTIN; METFORMIN; SIBUTRAMINE; TESTOSTERONE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ADRENAL GLAND; ANDROGEN RELEASE; ANDROGEN SYNTHESIS; BARIATRIC SURGERY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET THERAPY; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID STORAGE; LOW DRUG DOSE; NONHUMAN; OBESITY; OVARIECTOMY; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; STEROIDOGENESIS; WEIGHT REDUCTION;

ABDOMINAL FAT; ADIPOSITY; FEMALE; HUMANS; HYPERANDROGENISM; HYPERINSULINISM; INSULIN RESISTANCE; LEPTIN; MODELS, BIOLOGICAL; POLYCYSTIC OVARY SYNDROME;

EID: 34548215169     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2007.07.003     Document Type: Review

References (66)

1. Carmina E., and Lobo R.A. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J. Clin. Endocrinol. Metab. 84 (1999) 1897-1899
2. Diamanti-Kandarakis E., et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J. Clin. Endocrinol. Metab. 84 (1999) 4006-4011
3. Asunción M., et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J. Clin. Endocrinol. Metab. 85 (2000) 2434-2438
4. Azziz R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89 (2004) 2745-2749
5. Carmina E., et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J. Clin. Endocrinol. Metab. 92 (2007) 2500-2505
6. Zawadzki J.K., and Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A., et al. (Ed). Polycystic ovary syndrome Vol. 4 (1992), Blackwell Scientific Publications 377-384
7. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41-47
8. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J. Clin. Endocrinol. Metab. 91 (2006) 781-785
9. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J. Clin. Endocrinol. Metab. 91 (2006) 786-789
10. Azziz R., et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 91 (2006) 4237-4245
11. Wickenheisser J.K., et al. Human ovarian theca cells in culture. Trends Endocrinol. Metab. 17 (2006) 65-71
12. Escobar-Morreale H.F., et al. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr. Rev. 26 (2005) 251-282
13. Gambineri A., et al. Obesity and the polycystic ovary syndrome. Int. J. Obes. Relat. Metab. Disord. 26 (2002) 883-896
14. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr. Rev. 18 (1997) 774-800
15. Poretsky L., et al. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 20 (1999) 535-582
16. Poretsky L., et al. Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats. Metabolism 41 (1992) 903-910
17. DeClue T.J., et al. Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin-resistant female. J. Clin. Endocrinol. Metab. 72 (1991) 1308-1311
18. Fulghesu A.M., et al. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 82 (1997) 644-648
19. Jonard S., and Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum. Reprod. Update 10 (2004) 107-117
20. Alvarez-Blasco F., et al. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch. Intern. Med. 166 (2006) 2081-2086
21. Lo J.C., et al. Increased prevalence of gestational diabetes mellitus among women with diagnosed polycystic ovary syndrome: a population-based study. Diabetes Care 29 (2006) 1915-1917
22. Conn J.J., et al. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin. Endocrinol. (Oxf.) 52 (2000) 81-86
23. Peppard H.R., et al. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 24 (2001) 1050-1052
24. Musso C., et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 83 (2004) 209-222
25. Taylor S.I., et al. Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor. Ann. Intern. Med. 97 (1982) 851-855
26. Murray R.D., et al. Clinical presentation of PCOS following development of an insulinoma: case report. Hum. Reprod. 15 (2000) 86-88
27. Stanciu I.N., et al. Insulinoma presenting with hyperandrogenism: a case report and a literature review. J. Intern. Med. 253 (2003) 484-489
28. Codner E., and Escobar-Morreale H.F. Hyperandrogenism and polycystic ovary syndrome (PCOS) in women with type 1 diabetes Mellitus. J. Clin. Endocrinol. Metab. 92 (2007) 1209-1216
29. Goumenou A.G., et al. The role of leptin in fertility. Eur. J. Obstet. Gynecol. Reprod. Biol. 106 (2003) 118-124
30. Escobar-Morreale H.F., et al. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 90 (2005) 6364-6369
31. DeUgarte C.M., et al. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril. 83 (2005) 1454-1460
32. National Institutes of Health (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-The evidence report. Obes. Res. 6(Suppl 2), 51S-209S
33. Ehrmann D.A. Polycystic ovary syndrome. N. Engl. J. Med. 352 (2005) 1223-1236
34. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89 (2004) 2548-2556
35. Escobar-Morreale H.F., et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum. Reprod. 21 (2006) 2257-2265
36. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr. Rev. 24 (2003) 278-301
37. Duggal P.S., et al. The in vivo and in vitro effects of exogenous leptin on ovulation in the rat. Endocrinology 141 (2000) 1971-1976
38. Roby K.F., and Terranova P.F. Effects of tumor necrosis factor-alpha in vitro on steroidogenesis of healthy and atretic follicles of the rat: theca as a target. Endocrinology 126 (1990) 2711-2718
39. Spaczynski R.Z., et al. Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells. Biol. Reprod. 61 (1999) 993-998
40. Kaipia A., et al. Tumor necrosis factor-alpha and its second messenger, ceramide, stimulate apoptosis in cultured ovarian follicles. Endocrinology 137 (1996) 4864-4870
41. Spicer L.J. Tumor necrosis factor-alpha (TNF-alpha) inhibits steroidogenesis of bovine ovarian granulosa and thecal cells in vitro. Involvement of TNF-alpha receptors. Endocrine 8 (1998) 109-115
42. Spicer L.J., and Francisco C.C. Adipose obese gene product, leptin, inhibits bovine ovarian thecal cell steroidogenesis. Biol. Reprod. 58 (1998) 207-212
43. Path G., et al. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J. Clin. Endocrinol. Metab. 82 (1997) 2343-2349
44. Nagamani M., et al. Hyperinsulinemia in hyperthecosis of the ovaries. Am. J. Obstet. Gynecol. 154 (1986) 384-389
45. Dunaif A., et al. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 70 (1990) 699-704
46. Elbers J.M., et al. Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin. Endocrinol. (Oxf.) 58 (2003) 562-571
47. Abbott D.H., et al. Fetal programming of polycystic ovary syndrome. In: Kovacs G., and Norman R. (Eds). Polycystic ovary syndrome (2007), Cambridge University Press 262-287
48. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract. Res. Clin. Endocrinol. Metab. 16 (2002) 263-272
49. Xita N., and Tsatsoulis A. Review: Fetal programming of polycystic ovary syndrome by androgen excess: evidence from experimental, clinical, and genetic association studies. J. Clin. Endocrinol. Metab. 91 (2006) 1660-1666
50. Barnes R.B., et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J. Clin. Endocrinol. Metab. 79 (1994) 1328-1333
51. Beck-Peccoz P., et al. Maturation of hypothalamic-pituitary-gonadal function in normal human fetuses: circulating levels of gonadotropins, their common alpha-subunit and free testosterone, and discrepancy between immunological and biological activities of circulating follicle-stimulating hormone. J. Clin. Endocrinol. Metab. 73 (1991) 525-532
52. McClamrock H.D., and Adashi E.Y. Gestational hyperandrogenism. Fertil. Steril. 57 (1992) 257-274
53. Corton M., et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92 (2007) 328-337
54. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
55. Gonzalez F., et al. Evidence for heterogeneous etiologies of adrenal dysfunction in polycystic ovary syndrome. Fertil. Steril. 66 (1996) 354-361
56. Escobar-Morreale H.F., et al. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46 (2003) 625-633
57. Fenkci V., et al. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil. Steril. 80 (2003) 123-127
58. Gonzalez F., et al. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 91 (2006) 336-340
59. Norman R.J., et al. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol. Metab. 13 (2002) 251-257
60. De Leo V., et al. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr. Rev. 24 (2003) 633-667
61. Jayagopal V., et al. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 90 (2005) 729-733
62. Sabuncu T., et al. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil. Steril. 80 (2003) 1199-1204
63. Gambineri A., et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 60 (2004) 241-249
64. Gambineri A., et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J. Clin. Endocrinol. Metab. 91 (2006) 3970-3980
65. Ibanez L., and de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum. Reprod. Update 12 (2006) 243-252
66. Ibanez L., et al. Additive effects of insulin-sensitizing and anti-androgen treatment in young, nonobese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J. Clin. Endocrinol. Metab. 87 (2002) 2870-2874